ClinicalTrials.gg
RecruitingNCT07655869Updated Jun 18, 2026

[177Lu]Lu-DOTA-EB-RGD2 Therapy in Patients With Recurrent High-grade Glioma

An Early Phase 1 interventional study of [177Lu]Lu-DOTA-EB-RGD2 in Recurrent High-Grade Gliomas and Recurrent Glioblastoma IDH Wildtype, sponsored by Beijing Tiantan Hospital. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by Beijing Tiantan Hospital · Early Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Glioblastoma by Beijing Tiantan Hospital — 4 open to participants now, 5 under way, 1 of them phase 3. Glioblastoma · Beijing Tiantan Hospital.

Planned enrollment
6th of 10
24 · median 27
Started
2026
with 2 others
Phase 1
7 of 11
3 open now
Registered
9th of 11
by date

Among the 11 studies in Glioblastoma by Beijing Tiantan Hospital, this one is the 6th largest by planned enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2026, is one of 7 in phase 1, and was the 9th registered.

Glioblastoma

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

4 of the 11 studies in Glioblastoma by Beijing Tiantan Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Glioblastoma by Beijing Tiantan Hospital, or all of them as a file.
02

Study summary

This is an investigator-initiated, Phase I clinical trial. It aims to evaluate the safety, tolerability, dosimetry, and preliminary anti-tumor activity of a novel radiopharmaceutical, [177Lu]Lu-DOTA-EB-RGD2, in patients with recurrent high-grade gliomas. Participants will receive the drug either via intravenous infusion or directly into the tumor cavity through a pre-implanted Ommaya reservoir (a subcutaneously placed device that allows direct access to the tumor cavity). The study employs a "3+3" dose-escalation design to determine the maximum tolerated dose (MTD). Adverse events, biodistribution, and tumor response (by MRI) will be assessed. Approximately 24 patients will be enrolled across two major Chinese medical centers: Beijing Tiantan Hospital and Peking Union Medical College Hospital.

Read the detailed description

This is a multicenter, open-label, Phase I dose-escalation study with two parallel routes of administration: intravenous (IV) and locoregional (via Ommaya reservoir into the tumor cavity). The primary objective is to determine the maximum tolerated dose (MTD) of [177Lu]Lu-DOTA-EB-RGD2 for each route using a standard "3+3" design. Three dose levels per cycle are planned for each route (IV and locoregional). Treatment is given every 3 weeks for up to 2 cycles, with possible additional cycles based on clinical benefit as judged by the investigator.

Primary endpoint: Dose-limiting toxicity (DLT) incidence during the first 6 weeks (2 cycles), graded by CTCAE v5.0.

Secondary endpoints: Adverse events (type, frequency, severity); time-activity curves and absorbed radiation doses in organs and tumors (based on whole-body planar imaging and SPECT/CT at multiple time points); pharmacokinetic parameters (AUC, Cmax, Tmax, clearance [CL], volume of distribution [Vz], terminal half-life) from blood and urine sampling; objective response rate (ORR) per RANO 2.0 (by contrast-enhanced MRI); overall survival.

Exploratory endpoints: Change in tumor αvβ3 integrin expression by NOTA-PRGD2 PET/CT; correlation between baseline NOTA-PRGD2 PET uptake and treatment response.

Sample size: Approximately 24 patients (up to 3+3 per dose level per route) using the 3+3 rule. No formal hypothesis testing is planned; descriptive statistics will be used.

Study duration: 36 months (recruitment approximately 12 months, treatment and follow-up approximately 24 months). The trial is conducted at Beijing Tiantan Hospital and Peking Union Medical College Hospital, China.

03

Conditions studied

  • Recurrent High-Grade Gliomas
  • Recurrent Glioblastoma IDH Wildtype

Browse trials for

Keywords

  • Recurrent High-Grade Gliomas
  • Integrin αvβ3
  • Targeted Radionuclide Therapy
  • Safety and Tolerability
  • Radiation Dosimetry
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The participant must sign the form before participation.
  2. Age ≥ 18 years.
  3. confirmed glioblastoma (WHO classification) after surgical resection or .
  4. Participants receiving (e.g., dexamethasone) must be on a stable or decreasing dose ≤ 4 mg/day (or equivalent) for at least 7 days before start of study treatment.
  5. Adequate bone marrow and organ function confirmed by laboratory tests performed ≤ 14 days before first study treatment:

    (ANC) ≥ 1.5 × 10⁹/L; count ≥ 100 × 10⁹/L; ≥ 10.0 g/dL; Serum creatinine ≤ 1.5 × (ULN); Total ≤ 1.5 × ULN; albumin ≥ 30 g/L; and AST \< 3 × ULN in absence of liver , or \< 5 × ULN if liver metastases present; Coagulation: (APTT) ≤ 2 × ULN, international normalized ratio (INR) ≤ 1.5 (if not receiving anticoagulation therapy);

  6. Evidence of disease progression (PD) by RANO 2.0 criteria confirming recurrence: ≥ 25% increase in product of perpendicular diameters or > 40% increase in tumor volume compared to baseline after initial treatment or best response, while on stable or increasing corticosteroid dose. Clinical deterioration or increased corticosteroid dose alone is insufficient. MRI contrast enhancement, MRS, and/or metabolic PET should help differentiate true progression from radiation necrosis/pseudoprogression. Also, at least one bi-dimensionally measurable contrast-enhancing lesion with shortest diameter ≥ 10 mm must be present on MRI.
  7. For participants receiving Ommaya reservoir implantation for locoregional administration, surgery must be completed at least 2 weeks before first radionuclide therapy, with no postoperative complications. Baseline MRI for efficacy assessment must be performed at least 2 weeks after implantation and before first radionuclide therapy.
  8. Tumor uptake confirmed by NOTA-PRGD2 PET/CT after diagnosis of recurrence and before radionuclide therapy. For participants with Ommaya reservoir, PET/CT must be performed at least 2 weeks after implantation and before first radionuclide therapy.
  9. > 6 months.
  10. Performance Status (KPS) score ≥ 50.

Exclusion criteria

Exclusion Criteria:

  1. Receiving any other concurrent treatment for glioblastoma outside this study.
  2. Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed from the start of [177Lu]Lu-DOTA-EB-RGD2 treatment until 6 months after treatment.
  3. Refusal to use effective during sexual intercourse from until 6 months after the last dose of study drug.
  4. Inability to tolerate imaging procedures, repeated blood sampling, or poor venous access.
  5. Cardiac dysfunction, cardiac disease history, or abnormalities indicating a major safety risk, including:

(1) Documented myocardial infarction, angina pectoris, cardiomyopathy, symptomatic pericarditis, or coronary artery bypass grafting within 6 months before enrollment.

(2) Long syndrome, family history of idiopathic sudden death or congenital long QT syndrome, or any of the following: (a) risk factors for torsade de pointes (TdP) including uncorrected hypocalcemia, hypokalemia, hypomagnesemia, history of heart failure, or clinically significant/symptomatic bradycardia; (b) use of medications known to prolong the QT interval and/or cause TdP that cannot be discontinued or replaced with a safer alternative (e.g., within 5 half-lives or 7 days before study drug); (c) inability to determine the Fridericia-corrected QT interval (QTcF).

(3) Clinically significant arrhythmia (e.g., ventricular tachycardia), complete left bundle branch block, high-grade atrioventricular block (e.g., bifascicular block, Mobitz type II, third-degree AV block).

(4) Resting QTcF ≥ 450 ms (male) or ≥ 460 ms (female). (5) (LVEF) \< 50% by echocardiography. (6) Uncontrolled hypertension defined as systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg, regardless of antihypertensive use.

6. Other within 5 years before study drug administration, except adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer after curative surgery, carcinoma in situ after curative surgery, or papillary thyroid cancer after curative surgery (hormonal therapy for non- prostate or breast cancer allowed).

7. Abnormal serum virology (, T. pallidum antibody, antibody, antibody). Patients with untreated active hepatitis B who are willing to receive anti-HBV therapy during study treatment are allowed; patients with inactive hepatitis B are allowed; patients with inactive hepatitis C (HCV antibody positive but HCV RNA below lower limit of detection) are allowed.

8. Use of bevacizumab for glioblastoma or supportive care (e.g., edema reduction) within 60 days before start of study treatment.

9. Patients with disease progression within the first 12 weeks after completion of radiotherapy are excluded from recurrent disease trials.

10. Prior intracranial locoregional drug therapy before [177Lu]Lu-DOTA-EB-RGD2 treatment.

11. Active intracranial or intratumoral hemorrhage detected by CT/MRI. 12. Seizure within 14 days before start of study treatment; epilepsy or increased intracranial pressure uncontrolled by medication.

13. Grade 4 myelosuppression from prior anticancer therapy that has not recovered within 2 weeks, or grade 3 myelosuppression requiring >6 weeks to recover.

14. Blood transfusion within 4 weeks before screening to meet eligibility criteria.

15. Known or delayed allergic reaction to any component of [177Lu]Lu-DOTA-EB-RGD2 or similar drugs.

16. Severe disease of the cardiac, respiratory, central nervous system, renal, hepatic, or other organ systems that, in the investigator's opinion, may increase participant safety risk.

17. Active infection requiring intravenous antibiotics (bacterial, fungal, or viral) within 4 weeks before first dose, or any other uncontrolled active infection deemed clinically significant by the investigator.

18. History of drug or alcohol abuse within one year before screening, long-term drug use, or psychiatric illness that may affect compliance.

19. Participation in another drug or device trial within 4 weeks before first dose.

Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Intravenous Administration of [177Lu]Lu-DOTA-EB-RGD2

    Participants receive \[177Lu\]Lu-DOTA-EB-RGD2 via intravenous infusion 20-30 minutes once every 3 weeks (Q3W) for up to 2 cycles (6 weeks). Dose escalation follows a 3+3 design with three dose levels per cycle. Additional cycles may be given based on clinical benefit.

    Drug: [177Lu]Lu-DOTA-EB-RGD2

  • Experimental
    Locoregional Administration of [177Lu]Lu-DOTA-EB-RGD2

    Participants receive \[177Lu\]Lu-DOTA-EB-RGD2 directly into the tumor cavity through a previously implanted Ommaya reservoir once every 3 weeks (Q3W) for up to 2 cycles (6 weeks). Dose escalation follows a 3+3 design with three dose levels per cycle. Additional cycles may be given based on clinical benefit.

    Drug: [177Lu]Lu-DOTA-EB-RGD2

Interventions

  • DrugLutetium-177Studies of Lutetium-177Lutetium-177 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    A long-circulating radiolabeled peptide targeting integrin αvβ3. The radiopharmaceutical consists of an RGD2 peptide conjugated to a DOTA chelator and an albumin-binding (EB) motif, labeled with Lutetium-177 (half-life 6.7 days). It is administered intravenously (20-30 min infusion) or locoregionally via Ommaya reservoir directly into the tumor cavity. The study evaluates safety, tolerability, dosimetry, and preliminary efficacy in recurrent high-grade glioma.

06

What researchers measure

Primary outcomes

  1. Incidence of Dose-Limiting Toxicities (DLTs)

    DLTs are defined as protocol-specified adverse events occurring during the first 6 weeks (2 cycles) after the first dose, graded by NCI CTCAE v5.0. DLTs include: Grade ≥3 neurological toxicities (e.g., grade 3 CNS necrosis, grade 3 decreased consciousness, grade 3 hydrocephalus, grade 3 seizure, grade 3 headache that lasts over 24 hours with treatments, grade ≥4 cerebral edema); Grade ≥3 hematologic toxicities (e.g., grade 3 febrile neutropenia, grade 3 anemia lasting \>7 days, grade 3 lymphopenia with infection, grade 4 neutropenia lasting \>7 days, grade 4 thrombocytopenia or grade 3 with bleeding); Any grade ≥3 non-hematologic toxicity (except transient grade 3 nausea/vomiting/diarrhea lasting \<3 days, grade 3 fatigue lasting \<1 week, or electrolyte abnormality lasting less than 72 hours and resolved by supportive care); Any Hy's law event (e.g., ALT or AST \> 3-fold upper limit normal); Death or significant clinical intervention related to the study drug.

    Time frame: Within 6 weeks (42 days) after the first dose (during the first two cycles; each cycle is 21 days)

Secondary outcomes

  1. Incidence and severity of adverse events (AEs)

    All adverse events (AEs), serious AEs (SAEs), treatment-emergent AEs (TEAEs), and deaths, graded by NCI CTCAE v5.0. Assessment includes changes in vital signs, physical examination, electrocardiogram (ECG), echocardiogram (for participants \>60 years), laboratory tests (hematology, serum chemistry, coagulation, urinalysis), and serum pregnancy test (for females of childbearing potential). AE resolution or progression is tracked throughout follow-up.

    Time frame: From the first dose (Day 1) until study completion (up to 17 months)

  2. Radiation Dosimetry

    Time-activity curves (TACs) derived from whole-body planar imaging and SPECT/CT at multiple time points post-injection. Absorbed doses to the tumor and major organs are calculated using the MIRD methodology.

    Time frame: From the first dose up to 192 hours (Day 8)

  3. Maximum Tolerated Dose (MTD)

    The highest dose level at which ≤1 of 6 participants experiences a DLT during the first 6 weeks (2 cycles), determined separately for the intravenous and locoregional administration arms using the 3+3 dose-escalation design.

    Time frame: Within 6 weeks (42 days) after the first dose

  4. Area Under the Concentration-Time Curve (AUC) of [177Lu]Lu-DOTA-EB-RGD2 in Blood

    AUC calculated from time zero to last measurable time point and/or to infinity, measured from venous blood samples.

    Time frame: Pre-dose; 5, 15, 30, 60 minutes; 2, 4, 24, 48, 72, 144, 192 hours post-dose (first cycle only; each cycle is 21 days)

  5. Objective Response Rate (ORR)

    Proportion of participants achieving complete response (CR) or partial response (PR) on contrast-enhanced MRI according to RANO 2.0 criteria. CR is defined as disappearance of all enhancing and non-enhancing lesions without new lesions; PR is defined as a ≥50% decrease in the product of perpendicular diameters from baseline.

    Time frame: Baseline, Day 22 (±3 days), Day 42 (±7 days), then every 6 weeks until progression, death, or start of new therapy (up to 17 months)

  6. Overall Survival (OS)

    Time from the first dose of \[177Lu\]Lu-DOTA-EB-RGD2 to death from any cause. Participants alive at study end or lost to follow-up are censored at their last known alive date.

    Time frame: From the first dose up to 17 months (study duration)

  7. Maximum Plasma Concentration (Cmax) of [177Lu]Lu-DOTA-EB-RGD2 in Blood

    Cmax directly observed from concentration-time data, measured from venous blood samples.

    Time frame: Pre-dose; 5, 15, 30, 60 minutes; 2, 4, 24, 48, 72, 144, 192 hours post-dose (first cycle only; each cycle is 21 days)

  8. Time to Maximum Plasma Concentration (Tmax) of [177Lu]Lu-DOTA-EB-RGD2 in Blood

    Tmax corresponding to Cmax, measured from venous blood samples.

    Time frame: Pre-dose; 5, 15, 30, 60 minutes; 2, 4, 24, 48, 72, 144, 192 hours post-dose (first cycle only; each cycle is 21 days)

  9. Systemic Clearance (CL) of [177Lu]Lu-DOTA-EB-RGD2 in Blood

    CL calculated as Dose/AUC, measured from venous blood samples.

    Time frame: Pre-dose; 5, 15, 30, 60 minutes; 2, 4, 24, 48, 72, 144, 192 hours post-dose (first cycle only; each cycle is 21 days)

  10. Volume of Distribution During Terminal Phase (Vz) of [177Lu]Lu-DOTA-EB-RGD2 in Blood

    Vz calculated as CL/λz, measured from venous blood samples.

    Time frame: Pre-dose; 5, 15, 30, 60 minutes; 2, 4, 24, 48, 72, 144, 192 hours post-dose (first cycle only; each cycle is 21 days)

  11. Terminal Half-Life (t1/2) of [177Lu]Lu-DOTA-EB-RGD2 in Blood

    t1/2 calculated from the terminal phase of the concentration-time curve, measured from venous blood samples.

    Time frame: Pre-dose; 5, 15, 30, 60 minutes; 2, 4, 24, 48, 72, 144, 192 hours post-dose (first cycle only; each cycle is 21 days)

Other outcomes

  1. Change in Tumor Uptake of NOTA-PRGD2 on PET/CT

    Changes in tumor SUVmax, SUVmean, and tumor-to-background ratio (TBR) from baseline to post-treatment PET/CT scans, as an exploratory biomarker of target engagement.

    Time frame: Baseline (within 42 days before the first dose) and Day 42 (±7 days) after the first dose

07

Study locations

2 of 2 sites recruiting
  • Beijing Tiantan Hospital, Capital Medical University
    Beijing, Beijing Municipality 100070, China
    Recruiting
    • Li'ao Wang, M.D. · Contactwangliao17@163.com · 15001171671
    • Deling Li, M.D. · Principal investigator
  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
    Beijing, Beijing Municipality 100730, China
    Recruiting
    • Zhaohui Zhu, M.D. · Contact13611093752@163.com · +86 15909835868
    • Zhaohui Zhu, M.D. · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided — The decision on whether to share individual participant data (IPD) has not yet been finalized. This is a Phase I investigator-initiated trial with a small sample size (approximately 24 participants). Data sharing will be considered in accordance with institutional policies, patient consent, and Chinese regulatory requirements. Any future sharing would require additional ethical approval and a data transfer agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Dec 2026, 6 months later.

Of 239 non-industry phase 1 interventional studies under Glioblastoma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 76. This study's planned 6 months is below that.

Counting every sponsor, half of 321 studies reached it within 44 months; a quarter within 29 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2026
First posted
Jun 18, 2026
StartEst.
Jun 1, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jan 31, 2027
Last update
Jun 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07655869
Responsible party
Deling Li (Vice President, Beijing Tiantan Hospital) — Principal investigator
First posted
Jun 18, 2026
Start date
Jun 1, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Jan 31, 2027 (estimated)
Last update
Jun 18, 2026

Study contacts

Li'ao Wang, M.D.
Contact
wangliao17@163.com
+86 15001171671
Deling Li, M.D.
Contact
lideling@bjtth.org
Deling Li, M.D.
principal investigator · Beijing Tiantan Hospital
Zhaohui Zhu
principal investigator · Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lutetium-177

Start the discussion